Measurement properties of EQ-5D-3L and EQ-5D-5L in recording self-reported health status in older patients with substantial multimorbidity and polypharmacy

Table 18 Assessment of responsiveness of the EQ-5D-3L and the EQ-5D-5L measures to changes in the VAS, for the subgroup in Ireland

	EQ-5D-3L at 6 months (mean)	EQ-5D-3L at 12 months (mean)	Difference between 12 and 6 months EQ-5D-3L (95% CI)	Effect size (Cohen’s D)^a	n	% reporting 3L score increase
3L-VAS
Improved	0.73	0.84	0.10 (− 0.02 to 0.24)	0.41	23	39
No change	0.92	0.71	− 0.20 (− 0.48 to 0.06)	− 0.67	12	25
Worsened	0.82	0.82	0.00 (− 0.08 to 0.09)	0.00	13	23

	EQ-5D-5L at 6 months (mean)	EQ-5D-5L at 12 months (mean)	Difference between 12 and 6 months EQ-5D-5L (95% CI)	Effect size (Cohen’s D)	n	% reporting 5L score increase
5L-VAS
Improved	0.76	0.83	0.06 (0.00 to 0.14)	0.30	23	48
No change	0.91	0.72	− 0.19 (− 0.47 to 0.09)	− 0.61	12	33
Worsened	0.84	0.81	− 0.02 (− 0.07 to 0.01)	− 0.18	13	23

^aCohen’s D effect sizes of between 0.2 and 0.5 are considered small, 0.5 and 0.8 moderate and > 0.8 large

ISSN: 1477-7525